GLP-1 & Incretin Science

What Is Amycretin? One Molecule, Two Receptors

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Amycretin is a unimolecular agonist of both the GLP-1 and amylin receptors developed by Novo Nordisk. Unlike CagriSema, which combines two separate molecules, amycretin engages both receptors from a single peptide. It exists in once-weekly subcutaneous and once-daily oral forms, and Phase 2 data reported up to 14.5% weight reduction at 36 weeks.

Key facts

Class
Unimolecular GLP-1 + amylin receptor agonist
Developer
Novo Nordisk
Formulations
Weekly subcutaneous and daily oral
Phase 2 population
448 adults with type 2 diabetes
Duration
Up to 36 weeks
Subcutaneous result
11.9% placebo-adjusted reduction
Oral result
7.6% placebo-adjusted reduction
Status
Advancing to Phase 3

Unimolecular versus combination

This is the technically interesting part. CagriSema achieves amylin and GLP-1 agonism by putting two engineered peptides in one syringe. Amycretin achieves it with one peptide that binds both receptors. Unimolecular design removes the need to match the pharmacokinetics of two separate agents and simplifies manufacturing, but it is a much harder molecule to engineer, the same problem that makes retatrutide's triple agonism notable.

What the Phase 2 trial tested

The study enrolled 448 adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. It was a combined multiple-ascending-dose design testing six weekly subcutaneous doses from 0.4 mg to 40 mg and three daily oral doses of 6 mg, 25 mg and 50 mg, over up to 36 weeks.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The results, and the detail worth noticing

Weight reduction reached up to 14.5% at 36 weeks against placebo, with the weekly subcutaneous formulation producing 11.9% placebo-adjusted reduction and the daily oral form 7.6%. The finding that attracted most attention was not the headline figure: at the higher doses, no weight-loss plateau had been reached by week 36 in either route. A curve that has not flattened at the end of a trial says the observed number is a floor for that duration, not a ceiling.

Tolerability

Adverse events were predominantly gastrointestinal and mostly mild to moderate, consistent with both the incretin and amylin classes. The profile was described as safe and well tolerated across both routes, though Phase 2 populations are small relative to what a full safety picture requires.

Why an oral form matters here

Amycretin is a peptide, so its daily oral form faces the same barriers that make oral peptides difficult: gastric acid, proteases, poor permeability. That an oral peptide route produced 7.6% placebo-adjusted reduction at all is the notable part, and it sits in direct contrast to orforglipron's approach of abandoning the peptide backbone entirely.

Frequently asked questions

How is amycretin different from CagriSema?

CagriSema is two molecules combined. Amycretin is one molecule that binds both receptors, which is harder to design but avoids having to match two pharmacokinetic profiles.

Is amycretin approved anywhere?

No. It completed Phase 2 and is advancing into Phase 3.

Why does 'no plateau at week 36' matter?

It means weight reduction was still continuing when the trial ended, so the reported figure reflects the trial's length rather than the compound's limit.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.